

Systemic Transplantation of Adult Multipotent Stem Cells Prevents Articular Cartilage Degeneration in a Mouse Model of Accelerated Ageing

Seth David Thompson

Northwestern University Interdepartmental Neuroscience Program

Rajeswari Pichika

Shirley Ryan AbilityLab

Richard L Lieber

Shirley Ryan AbilityLab

Mitra Lavasani (✉ mlavasani@sralab.org)

Shirley Ryan AbilityLab <https://orcid.org/0000-0002-2179-6947>

Research

Keywords: Progeria, Accelerated ageing, Articular cartilage, Adult stem cells, Transplantation, Regenerative medicine

Posted Date: August 19th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-58921/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Immunity & Ageing on June 7th, 2021. See the published version at <https://doi.org/10.1186/s12979-021-00239-8>.

**Systemic Transplantation of Adult Multipotent Stem Cells Prevents Articular Cartilage Degeneration
in a Mouse Model of Accelerated Ageing**

Running title

Systemic Rejuvenation of Progeroid Articular Cartilage

Seth D. Thompson^{1,2,3,*}, Rajeswari Pichika^{1,2,*}, Richard L. Lieber^{1,2}, Mitra Lavasani^{1,2,3}

¹Shirley Ryan AbilityLab, Chicago, USA, 60611

²Department of Physical Medicine and Rehabilitation, Northwestern University, Chicago, USA

³Northwestern University Interdepartmental Neuroscience (NUIN) Graduate Program, Northwestern University, Chicago, USA

*Equal Contribution

Correspondence to:

Mitra Lavasani, Ph.D.

Shirley Ryan Abilitylab (Formerly the Rehabilitation Institute of Chicago)

355 E. Erie St, Chicago, IL 60611

312-238-3427 **office**

312-503-3917 **fax**

Email: mlavasani@sralab.org

1 **ABSTRACT**

2

3 **Background.** Osteoarthritis (OA) is one of the most prevalent joint diseases of advanced age and is a
4 leading cause of disability worldwide. Ageing is a major risk factor for the articular cartilage (AC)
5 degeneration that leads to OA, and the age-related decline in regenerative capacity accelerates OA
6 progression. Here we demonstrate that systemic transplantation of a unique population of adult multipotent
7 muscle-derived stem/progenitor cells (MDSPCs), isolated from young wild-type mice, into *Zmpste24*^{-/-} mice
8 (a model of Hutchinson-Gilford progeria syndrome, a condition marked by accelerated ageing), prevents
9 ageing-related homeostatic decline of AC.

10 **Results.** MDSPC treatment inhibited expression of cartilage-degrading factors such as pro-inflammatory
11 cytokines and extracellular matrix-proteinases, whereas pro-regenerative markers associated with cartilage
12 mechanical support and tensile strength, cartilage resilience, chondrocyte proliferation and differentiation,
13 and cartilage growth, were increased. Notably, MDSPC transplantation also increased the expression level
14 of genes known for their key roles in immunomodulation, autophagy, stress resistance, pro-longevity, and
15 telomere protection. Our findings also indicate that MDSPC transplantation increased proteoglycan content
16 by regulating chondrocyte proliferation.

17 **Conclusions.** Together, these findings demonstrate the ability of systemically transplanted young
18 MDSPCs to preserve a healthy homeostasis and promote tissue regeneration at the molecular and tissue
19 level in progeroid AC. These results highlight the therapeutic potential of systemically delivered multipotent
20 adult stem cells to prevent age-associated AC degeneration.

21

22 **KEY WORDS**

23 Progeria, Accelerated ageing, Articular cartilage, Adult stem cells, Transplantation, Regenerative medicine

24

25 **BACKGROUND**

26

27 Ageing-related degeneration of the knee articular surface, degradation of aggrecans, and loss of matrix
28 tensile strength and stiffness [1, 2] results in osteoarthritis (OA), the most prevalent and debilitating joint

29 disease of advanced age and the leading cause of disability in older adults worldwide [3, 4]. Ageing results
30 in a disruption of cartilage homeostasis. Accumulation of catabolic factors—such as pro-inflammatory
31 cytokines, senescence-associated secretory phenotype (SASP) factors [5], and matrix metalloproteinases
32 (MMPs) alters the tissue microenvironment, contributes to oxidative stress, and can augment inflammatory
33 responses [6, 7]. With increasing age, chondrocyte density and responsiveness to proliferative and anabolic
34 factors are reduced [8, 9]. Because articular chondrocytes rely on autophagy as the primary mechanism for
35 maintaining healthy function and survival [10], the gradual decrease of chondrocyte autophagic activity
36 during ageing induces senescence, ultimately increasing OA severity [11].

37 While tissue- and cellular-level changes in aged cartilage have been characterized [12], an effective
38 therapy or preventative treatment for age-related articular cartilage (AC) degeneration has not been
39 developed. Current cellular treatments, including autologous chondrocyte implantation, autologous matrix-
40 induced chondrogenesis (AMIC), and intra-articular injection of mesenchymal stem cells, have been
41 effective for small, mainly injury-induced articular cartilage loss [13-16]; however, their effectiveness is
42 questionable in cases of cartilage degradation, rheumatic disease, and considerable restriction of joint
43 mobility, which substantially limits their applicability for the treatment of ageing-related changes [17].

44 We have isolated a unique population of adult multipotent stem cells, muscle-derived stem/progenitor
45 cells (MDSPCs), from skeletal muscle via a modified preplate technique [18]. MDSPCs have the capacity
46 for long-term proliferation, self-renewal, and multi-lineage differentiation, and are resistant to oxidative
47 stress, all of which likely contribute to their ability to promote regeneration [19-23]. MDSPCs have also been
48 shown to undergo chondrogenic differentiation in vitro and to repair cartilage defects as efficiently as
49 chondrocytes [23], after local transplantation in a young host, injury-induced OA model [24]. Previously, we
50 established that MDSPCs isolated from naturally aged and progeroid (i.e., accelerated ageing) mice
51 showed a reduction in stemness capacity, including proliferation and differentiation; however, these
52 phenotypic impairments were rescued by co-culture with, or by conditioned media from young MDSPCs
53 [22, 25]. In addition, we previously demonstrated that systemic transplantation of young MDSPCs into a
54 progeroid mouse model delayed the onset of multiple age-related pathologies, leading to a doubling of
55 lifespan and a significant extension of healthspan [22]. Together, these observations strongly suggest that
56 MDSPCs exert a therapeutic effect on the aged microenvironment by systemically-acting secreted factors.

57 *Zmpste24*^{-/-} mice are an established murine model of Hutchinson-Gilford progeria syndrome (HGPS),
58 which features many musculoskeletal degenerative changes similar to those of advanced ageing [26-29].
59 HGPS is manifested predominantly in the connective tissue, with the most prominent histological changes
60 observed in the cartilage, bone, skin, and cardiovascular tissues [30]. Here, we report that systemic
61 transplantation of MDSPCs rejuvenates progeroid AC at the molecular and tissue levels in *Zmpste24*^{-/-}
62 mice.

63

64 RESULTS

65

66 Articular cartilage of progeroid mice shows ageing-related imbalances associated with local 67 catabolic and anabolic activity

68

69 To identify age-associated articular cartilage (AC) changes in progeroid mice, gene expression in knee
70 joints of 5-6 month-old *Zmpste24*^{-/-} mice was compared to that of age-matched wild-type (WT) littermates.
71 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used to assess expression
72 of genes encoding pro-inflammatory cytokines, extracellular matrix (ECM) proteinases, and ECM
73 components (Fig. 1). In the AC of progeroid mice, we observed a statistically significant increase in *Il1a*,
74 *Il6*, and *Tnf*—pro-inflammatory factors associated with the senescence-associated secretory phenotype
75 (SASP)—compared to WT littermates (Fig.1a). Gene expression of *Mmp3*, *Mmp13*, and *Adamts5*—
76 catabolic factors involved with cleaving ECM components such as collagen type II and aggrecans, [31, 32]
77 [33] were also significantly increased in *Zmpste24*^{-/-} progeroid mice (Fig. 1b). In addition, we observed a
78 significant increase in the expression level of *Col1a1*, responsible for cartilage tensile strength and stiffness,
79 in the articular cartilage of *Zmpste24*^{-/-} progeroid mice compared to WT littermates; however, the
80 expression level of pro-regenerative matrix cellular components such as *Col2a1*, *Acan*, *Vcan*, and *Bgn* were
81 not significantly altered (Fig. 1c). Of note, we did not observe a significant difference in telomere protection
82 (*Pot1b*) or autophagy suppression (*Mtor*) genes in *Zmpste24*^{-/-} progeroid mice compared to WT mice (Fig.
83 1d). Furthermore, the antioxidant response gene (*Gpx*) was significantly increased in progeroid mice
84 compared to WT mice, while no change was observed in oxidative stress-response (*Sod1*) expression.

85 (Fig. 1e). Taken together, these findings demonstrate a catabolic-anabolic imbalance in the AC of progeroid
86 *Zmpste24*^{-/-} mice.

87

88 **Systemic transplantation of young MDSPCs preserves healthy articular cartilage homeostasis in** 89 **progeroid mice**

90

91 To determine whether the loss of AC homeostasis due to accelerated ageing in *Zmpste24*^{-/-} mice can be
92 prevented, we investigated the effect of systemic transplantation of young MDSPCs on the AC
93 microenvironment. Littermate pairs of *Zmpste24*^{-/-} mice were injected intraperitoneally (IP) with 2x10⁵
94 young MDSPCs per gram of body weight (Z-IP) or an equal volume of PBS (Z-PBS) at 2 months of age
95 and again at 4 months of age (Fig. 2a). The AC from the knee joints was processed at 5-6 months of age
96 and gene expression was measured using qRT-PCR. The expression of genes associated with pro-
97 inflammatory cytokines and SASP factors, including *Il1a*, *Il6*, and *Tnf*, which are upregulated during ageing
98 and enhance matrix degradation [34], were significantly downregulated in Z-IP articular cartilage compared
99 to Z-PBS littermates (Fig. 2b). Importantly, the expression of *Il10*, an immunomodulatory and anti-
100 inflammatory cytokine, was significantly increased in Z-IP mice (Fig. 2b). Gene expression of *Mmp3*,
101 *Mmp13*, and *Adamts5* were also significantly decreased in articular cartilage of Z-IP mice compared with
102 Z-PBS mice (Fig. 2c). Moreover, Z-IP mice showed significant increases in expression of genes responsible
103 for cartilage mechanical support and tissue repair (*Col2a1*), cartilage resilience (*Acan*), chondrocyte
104 proliferation and differentiation (*Vcan*), and cartilage growth (*Bgn*) compared to Z-PBS mice (Fig. 2d) [35-
105 38]. Of note, we did not observe a difference in *Col1a1* gene expression between treatment groups. These
106 data provide evidence that MDSPC transplantation inhibited genes that promote cartilage degradation while
107 activating pro-regenerative genes, thereby preserving a healthy anabolic-catabolic balance in progeroid
108 AC.

109

110 **Systemic transplantation of young MDSPCs alters expression of ageing-related genes in articular** 111 **cartilage of progeroid mice**

112

113 We next investigated whether MDSPC transplantation can prevent the changes in expression of key
114 ageing-related genes in the AC of *Zmpste24*^{-/-} progeroid mice (Fig. 3). Our results demonstrate that
115 MDSPC transplantation significantly down-regulated *Nfkb1*, the master regulator and transcription factor
116 most highly correlated with ageing. Interestingly, the expression level of the NF-κB inhibitor, *Nfkbia*, was
117 significantly upregulated in Z-IP mice (Fig. 3a) compared to Z-PBS littermates. Our results also revealed a
118 significant increase in the FoxO transcription factors, *Foxo3* and *Foxo1*, in the AC of Z-IP mice compared
119 to Z-PBS mice (Fig. 3a). With age, chondrocytes exhibit senescent phenotypes, including telomere
120 shortening [39]. Notably, the telomere protection gene *Pot1b*, known as a pro-longevity marker, [40] was
121 robustly increased in the cartilage of Z-IP mice (Fig. 3a). MDSPC transplantation significantly decreased
122 the expression level of the oxidative stress-response gene *Sod1*, the antioxidant enzyme glutathione
123 peroxidase 4 (*Gpx4*), and the growth arrest and DNA damage response gene *Gadd45a*, compared to Z-
124 PBS mice (Fig. 3b). We did not detect any differences in *Mtor*—the key regulator and suppressor of
125 autophagy during ageing (Fig. 3c). Also, the expression level of stress-induced senescence gene *Cav1* [41,
126 42]—a major component of the caveolae structure and a transmembrane protein, and of cellular
127 senescence gene *Cdkn2a*, also known as p16 [43], did not change following MDSPC transplantation (Fig.
128 3c). Together, these results indicate MDSPC transplantation restores aged articular cartilage homeostasis
129 and improves maintenance at a molecular level.

130

131 **Systemic transplantation of young MDSPCs rejuvenates articular cartilage in *Zmpste24*^{-/-} progeroid** 132 **mice**

133

134 To determine whether MDSPC treatment maintains healthy AC tissue structure by preventing the loss of
135 ECM proteoglycans, knee joints were stained with Safranin-O (Saf-O). Saf-O staining in the femoral condyle
136 and tibial plateau (Fig. 4a) of the articular cartilage revealed striking changes between Z-IP and Z-PBS
137 mice. In fact, while both groups maintained a similar overall total cartilage area (Fig. 4b), 69% of the
138 cartilage area in Z-IP mice was Saf-O⁺ compared to only 23% in Z-PBS mice (Fig. 4c), indicating
139 proteoglycan enrichment after MDSPC transplantation. The knee joints of Z-IP mice also had a greater
140 number of chondrocytes and density compared to Z-PBS control mice (Fig. 4d and e). Together, these

141 findings strongly suggest that MDSPC treatment confers protection against the loss of AC matrix, in part by
142 increasing cartilage cellularity and preventing age-associated degradation.

143

144 **DISCUSSION**

145

146 Given that AC degeneration causes OA, a significant cause of disability worldwide, we sought to identify
147 age-related changes in the cartilage microenvironment in a mouse model of accelerated ageing.
148 Furthermore, we evaluated an intervention to delay or reverse the degenerative effects of accelerated
149 ageing. Here, we report, for the first time, the prevention of progeroid AC degeneration—at the molecular
150 and tissue levels—by systemic transplantation of young WT MDSPCs.

151 *Zmpste24*^{-/-} mice exhibit gene expression signatures robustly associated with ageing in AC—such as
152 increased SASP factors including pro-inflammatory cytokines (*Il1a* and *Il6*) and catabolic matrix-degrading
153 proteinases (*Mmp3*, *Mmp13*, and *Adamts5*), which further drive age-associated pathologies such as
154 hypertrophic chondrocyte differentiation. However, after MDSPC treatment, *Zmpste24*^{-/-} gene expression
155 profiles remained similar to those of WT littermates [12, 36]. Furthermore, the immunomodulating and anti-
156 inflammatory cytokine *Il10* and an ECM component that plays an important role in tissue remodeling and
157 repair, *Col2a1* [37], were upregulated in the AC of Z-IP mice. Rejuvenation was also supported by increased
158 expression of vital matrix proteoglycans *Acan*, *Vcan*, and *Bgn*, which are responsible for cartilage tensile
159 strength, resilience, and cartilage growth. Together, these results demonstrate the restoration of progeroid
160 cartilage to a “healthy” state.

161 The fact that systemic transplantation provides such a remarkable improvement in progeroid AC,
162 reinforces our hypothesis that the observed effects are induced via secreted paracrine/endocrine factors.
163 This is consistent with our previous reports [22, 25] where young (but not old) MDSPCs restored the
164 dysfunction of progeroid and naturally aged MDSPCs when co-cultured in vitro, and that transplantation of
165 young MDSPCs extended both the lifespan and healthspan of progeroid mice through systemically acting
166 secreted factors. The underlying mechanism(s) of action for this rejuvenation still remains unknown, but
167 our ongoing studies focus on the mechanistic basis of MDSPC systemic effects. We hypothesize that
168 MDSPCs promote the maintenance of healthy AC by secreting chondrocyte-protecting cytokines/growth

169 factors, thereby regulating chondrocyte viability and sensitivity to extrinsic factors and reducing articular
170 cartilage degeneration. In fact, MDSPCs are known to perform a variety of biological functions, including
171 immune regulation, angiogenesis, anti-apoptosis, anti-oxidant, cell homing, and promotion of tissue-specific
172 cell differentiation [44]. Therefore, it is not far-fetched to suggest that pro-regenerative factors secreted by
173 MDSPCs preserves the local AC microenvironment in progeroid mice by increasing anabolic activity while
174 simultaneously inhibiting catabolic activity.

175 The fact that the DNA damage-inducible and oxidative stress genes *Gadd45a*, *Sod1*, *Gpx4*, were all
176 significantly decreased following systemic transplantation, indicates that MDSPCs may also preserve AC
177 through cyto-protective mechanisms. This is supported by the observation that we measured a profound
178 increase in expression of the telomere protection gene, *Pot1b*, demonstrating a protective effect of
179 MDSPCs on chromosomal stability. In fact, recent studies have shown that maintenance of telomere length
180 can reverse neurodegeneration, delay metabolic ageing in mice, and increase lifespan [40, 45].

181 The transcription factor NF- κ B, a central controller and mediator of ageing-related signaling pathways,
182 regulates many immune responses [46] and is also a candidate activator of many ageing-related
183 transcriptional changes in human and mouse tissues, particularly stress-inducing stimuli such as pro-
184 inflammatory factors and SASPs [47]. Previous studies by Robbins *et al.* indicate that *Nfkb1* transcriptional
185 activity is up-regulated in a variety of tissues in both natural ageing and in mouse models of human progeria
186 caused by defective DNA damage repair mechanisms [48]. Skin-derived human fibroblasts from HGPS
187 patients and aged individuals also show increased inflammatory gene expression and increased levels of
188 NF- κ B activation compared to cells from young individuals [47, 49]. Similar to previous reports [50],
189 systemic transplantation of MDSPCs results in significant reduction of *Nfkb1* expression and an increase
190 in expression of the *Nfkb1* inhibitor, *Nfkbia*. Further studies are needed to investigate the mechanism(s)
191 underlying modulation of NF- κ B and other inflammatory factors.

192 Defective autophagy is a key feature of age-related diseases, and recent observations indicate that this
193 process is compromised in ageing cartilage [51, 52] through FoxO downregulation [53]. FoxO transcription
194 factors, which have recently been found to play vital roles in postnatal cartilage development, maturation,
195 homeostasis, and protection against OA-associated cartilage damage [53] as well as to protect against
196 cellular ageing and to enhance autophagy, are suppressed in human OA and mouse cartilage [11, 54].

197 *Foxo1* and *Foxo3* regulate chondrocyte proliferation and differentiation [53] and their expression levels are
198 reduced in both ageing and OA-affected cartilage in humans and mice [53]. In our study, the prominent
199 upregulation of *Foxo1* and *Foxo3* in AC in MDSPC-treated mice suggests that our cellular therapy prevents
200 chondrocyte ageing and delays the onset of OA-like symptoms, in part, through these mechanisms. It
201 appears that, by preserving cartilage cellularity, the bioactive paracrine/endocrine factors secreted by
202 MDSPCs had beneficial effects on the aged cartilage tissue microenvironment, leading to more favorable
203 conditions for tissue regeneration. This results in increased chondrocyte density and an enrichment of ECM
204 proteoglycans, thereby maintaining more normal knee joint histology.

205 Collectively, our results suggest that the mechanisms behind AC rejuvenation in progeroid mice are in
206 part due to activation of telomere protection mechanisms, modulation of the inflammatory SASP cascade,
207 and maintenance of pro-regenerative and pro-longevity pathways. Further studies will identify MDSPC
208 secretomes, specifically those which are activated after IP transplantation. Limitations of this study include
209 that we did not assess functional effects of MDSPC transplantation or possible effects of sex differences
210 between donor and host. Future studies will investigate if the observed restoration of AC at the molecular
211 and cellular levels after MDSPC systemic transplantation lead to functional stability or improvement in
212 progeroid mice.

213

214 **CONCLUSIONS**

215

216 These results demonstrate that treating a mouse model of accelerated ageing with a systemic injection of
217 young multipotent adult stem cells prevents age-related cartilage degradation and maintains the
218 catabolic/anabolic balance in host tissues. This cellular treatment promotes a “healthy” homeostasis and
219 stimulates tissue regeneration. Young MDSPCs, and/or their secreted factors, thus represent a potential
220 novel therapeutic strategy for preventing or treating age-related AC degeneration.

221

222

223

224

225 **METHODS**

226

227 **MDSPC isolation**

228

229 Young WT MDSPCs were isolated from the hindlimb skeletal muscle of 21 day-old female mice via a
230 modified preplate technique [18]. MDSPCs were cultured and expanded for transplantation in proliferation
231 medium (PM): Hi-glucose DMEM supplemented with 10% horse serum, 10% fetal-bovine serum (FBS), 1%
232 penicillin-streptomycin (all from Invitrogen), and 0.5% chick embryo extract (CEE, Accurate Chemical).
233 Cells are cultured on collagen type I-coated flasks.

234

235 **Animal Husbandry**

236

237 All animal experiments were performed with the approval of the Northwestern University Institutional Animal
238 Care and Use Committee. 17-day-old mice are ear tagged and tail snips are collected and mailed through
239 the Northwestern University in-house system to Transnetyx for genotyping. Results are received within 72
240 hours with over 99.9% accuracy. Primers and PCR conditions for genotyping *Zmpte24*^{-/-} mice have been
241 previously published [29]. Mice were maintained in a pathogen-free facility at 23-24 °C under a 12-hr light,
242 12-hr dark regimen and fed ad libitum a standard chow which is gamma-irradiated. Mice were always
243 studied in sibling pairs to minimize environmental variables. Only if breeding produces two or more
244 *Zmpte24*^{-/-} mice would the litter be used in an exposure study so that one mutant animal is treated with the
245 experimental treatment and the other receives vehicle only.

246

247 **Cell Transplantation**

248

249 MDSPCs suspended in 50 µL of buffered saline (PBS) were transplanted via intraperitoneal (IP)
250 administration into 4-5-monthold *Zmpte24*^{-/-} mice at 2 x 10⁵ MDSPCs per gram body-weight. A littermate
251 mutant animal was injected with vehicle only (PBS). The injection was repeated 2 months later. Mice were
252 sacrificed at 5-6 months of age and the right hind limbs were harvested for histopathological analysis and

253 the left knee joint were isolated for gene expression analysis. Both male and female mice were included in
254 the transplantation study.

255

256 **Histology**

257

258 Right hind limbs were fixed in PFA for 2 days, stored in PBS at 4°C overnight, and then paraffin embedded.

259 Sections were cut to 4 µm, collected at 100 µm intervals, and stained with Safranin O (Saf-O)–Fast Green
260 as described previously to evaluate the proteoglycan content and pathological changes such as cartilage
261 degradation [55].

262

263 **Histomorphometry**

264

265 Histomorphometric analyses were performed using NIS-Elements software (Nikon, AR 5.11.03). The Saf-
266 O+ area was measured impartially by the NIS software using identical thresholding parameters between all
267 images (pixels falling below the threshold intensity of 20 were uncounted) by detecting the total red (Saf-
268 O+) pixel area. The total cartilage area was manually selected with border detection assistance using the
269 NIS software's thresholding tools. Saf-O+ chondrocytes were manually counted for each femoral condyle
270 and tibial plateau and graphed as average Saf-O+ chondrocytes and number of Saf-O+ chondrocytes per
271 mm² of total articular cartilage. Chondrocytes were considered Saf-O+ if they were surrounded by red-
272 stained matrix.

273

274 **RNA isolation and qPCR**

275

276 To measure mRNA expression, total RNA was extracted from articular cartilage isolated from
277 paraformaldehyde (PFA)-fixed knee joints using an RNeasy® mini kit for formalin-fixed, paraffin-embedded
278 (FFPE) tissue (Qiagen) according to manufacturer's protocol. RNA quality was validated using an
279 Eppendorf Bio-Spectrophotometer, and 100 ng of total RNA was reverse-transcribed according to the
280 manufacture's protocol using iScript Advanced cDNA synthesis kit (Bio-Rad Laboratories). Pre-

281 amplification of the primers was carried out according to the manufacturer's protocol using a Pre-
282 amplification kit (Bio-Rad Laboratories). The pre-amplified cDNA was diluted and used for analysis of gene
283 expression changes in 10 μ L reactions using SYBR green advanced master mix kit (Bio-Rad Laboratories)
284 and the gene of interest primer pairs. Data were analyzed with the Δ Ct method and gene expression was
285 normalized to average expression of Gapdh and Hmbg1. Primers for the genes of interest were obtained
286 from Bio-Rad Laboratories and the primer catalog identification IDs are listed in Table 1.

287

288 **Statistics**

289

290 Statistical analyses were carried out using the SigmaPlot (Jandel Scientific v14.0) software package. The
291 two-tailed unpaired Welch's unequal variance *t*-test, two-tailed Student *t*-test, or the Mann-Whitney Rank
292 sum test were used where appropriate for direct comparisons between treatment and control groups. All
293 values are expressed as the mean \pm SEM., and $p < 0.05$ was considered significant.

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309 **TABLE 1** Primer list

310

Gene name	Traditional classification (Common name)	Catalog identification
<i>Acan</i>	Aggrecan	qMmuCED0046843
<i>Adamts5</i>	a-disintegrin and metalloproteinase with thrombospondin motif 5	qMmuCED0045481
<i>Bgn</i>	Biglycan	qMmuCED0046901
<i>Cav1</i>	Caveolin 1	qMmuCID0020997
<i>Cdkn2a</i>	Cyclin dependent kinase inhibitor 2a	qMmuCED0038108
<i>Col1a1</i>	Collagen type I alpha 1	qMuCED0044222
<i>Col2a1</i>	Collagen type 2 a1	qMuCID0006546
<i>Col10a1</i>	Collagen type 10 alpha1	qMuCID0008115
<i>Foxo1</i>	Fork head box transcription factor 1	qMmuCID0016391
<i>Foxo3</i>	Fork head box transcription factor 3	qMmuCED0004522
<i>Gadd45a</i>	Growth arrest and DNA damage inducible alpha	qMmuCED0001074
<i>Gapdh</i>	Glyceraldehyde 3-phosphate dehydrogenase	qMmuCED0027497
<i>Gpx4</i>	Glutathione peroxidase	qMmuCED0001062
<i>Il1a</i>	Interleukin 1 alpha	qMmuCID005637
<i>Il6</i>	Interleukin 6	qMmuCED0045760
<i>Il10</i>	Interleukin 10	qMmuCED0044967
<i>Mmp3</i>	Matrix metalloproteinase 3	qMmuCED0049170
<i>Mmp13</i>	Matrix metalloproteinase 13	qMmuCED0050490
<i>Mtor</i>	Mammalian target of rapamycin	qMmuCED0047795
<i>Nfkb1</i>	Nuclear factor kappa b1	qMmuCID0005357
<i>Nfkbia</i>	Nuclear factor kappa b inhibitor	qMmuCED0045043
<i>Pot1b</i>	Protection of telomeres 1b	qMmuCED0045942
<i>Sod1</i>	Superoxide dismutase 1	qMmuCID0026086
<i>Tnf</i>	Tumor necrosis factor	qMmuCED004141
<i>Vcan</i>	Versican	qMmuCED0046650

311

312

313

314 **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

315

316 Not applicable

317

318 **CONSENT FOR PUBLICATION**

319

320 Not applicable

321

322 **AVAILABILITY OF DATA AND MATERIALS**

323

324 The datasets used and/or analyzed during the current study are available from the corresponding author
325 on reasonable request.

326

327 **COMPETING INTERESTS**

328

329 The authors declare that they have no competing interests.

330

331 **FUNDING**

332

333 This work was supported by the Christopher L. Moseley Foundation, the Lisa Dean Moseley Foundation,
334 and an Innovative Catalyst Grant Award from Shirley Ryan AbilityLab to M.L. and a Research Career
335 Scientist Award, Number IK6 RX003351, from the United States Department of Veterans Affairs
336 Rehabilitation R&D Service to R.L.L.

337

338 **AUTHORS' CONTRIBUTIONS**

339

340 S.D.T. contributed to experimental design, cell transplantation, microscopy imaging of cartilage tissues,
341 histological analysis, and prepared the manuscript. R.P. contributed to experimental design, qRT-PCR,

342 genetic analysis, and histological analysis. R.L.L. contributed to experimental design and manuscript
343 editing. M.L. conceived and oversaw all experiments, performed cell transplantation, data interpretation,
344 statistical analysis, and edited the manuscript. All authors critically revised and approved the final version
345 of the manuscript.

346

347 **ACKNOWLEDGEMENTS**

348

349 We would like to thank Dr. Carlos Lopez-Otin for kindly providing the breeding pairs of *Zmpste24*^{-/-} mice
350 from University of Oviedo, Spain, Katherine Gruner and Alicia Steffens at the Northwestern Mouse
351 Histology and Phenotyping Laboratory for their expertise and assistance processing the articular cartilage
352 tissues, and Dr. Ann Barlow for her editorial assistance.

353

354 **REFERENCES**

355

356 1. Wells T, Davidson C, Morgelin M, Bird JL, Bayliss MT, Dudhia J. Age-related changes in the
357 composition, the molecular stoichiometry and the stability of proteoglycan aggregates extracted from
358 human articular cartilage. *Biochem J.* 2003;370(Pt 1):69-79.

359 2. Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A, Bank RA, et al. Crosslinking by
360 advanced glycation end products increases the stiffness of the collagen network in human articular
361 cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. *Arthritis Rheum.*
362 2002;46(1):114-23.

363 3. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the
364 prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum.*
365 1998;41(5):778-99.

366 4. DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs)
367 for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-
368 2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017;390(10100):1260-
369 344.

- 370 5. Soto-Gamez A, Demaria M. Therapeutic interventions for aging: the case of cellular senescence.
371 Drug Discov Today. 2017;22(5):786-95.
- 372 6. Greene MA, Loeser RF. Aging-related inflammation in osteoarthritis. *Osteoarthritis Cartilage*.
373 2015;23(11):1966-71.
- 374 7. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular senescence:
375 causes and consequences. *Trends Mol Med*. 2010;16(5):238-46.
- 376 8. Loeser RF. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the
377 cartilage matrix. *Osteoarthritis Cartilage*. 2009;17(8):971-9.
- 378 9. Loeser RF. Aging and osteoarthritis. *Curr Opin Rheumatol*. 2011;23(5):492-6.
- 379 10. Terman A, Kurz T, Navratil M, Arriaga EA, Brunk UT. Mitochondrial turnover and aging of long-
380 lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging. *Antioxid Redox Signal*.
381 2010;12(4):503-35.
- 382 11. Carames B, Taniguchi N, Otsuki S, Blanco FJ, Lotz M. Autophagy is a protective mechanism in
383 normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. *Arthritis Rheum*.
384 2010;62(3):791-801.
- 385 12. Lotz M, Loeser RF. Effects of aging on articular cartilage homeostasis. *Bone*. 2012;51(2):241-8.
- 386 13. Krill M, Early N, Everhart JS, Flanigan DC. Autologous Chondrocyte Implantation (ACI) for Knee
387 Cartilage Defects: A Review of Indications, Technique, and Outcomes. *JBJS Rev*. 2018;6(2):e5.
- 388 14. Davatchi F, Sadeghi Abdollahi B, Mohyeddin M, Nikbin B. Mesenchymal stem cell therapy for knee
389 osteoarthritis: 5 years follow-up of three patients. *Int J Rheum Dis*. 2016;19(3):219-25.
- 390 15. Al-Najar M, Khalil H, Al-Ajlouni J, Al-Antary E, Hamdan M, Rahmeh R, et al. Intra-articular injection
391 of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is
392 safe: a phase I/II study. *J Orthop Surg Res*. 2017;12(1):190.
- 393 16. Bartlett W, Skinner JA, Gooding CR, Carrington RW, Flanagan AM, Briggs TW, et al. Autologous
394 chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral
395 defects of the knee: a prospective, randomised study. *J Bone Joint Surg Br*. 2005;87(5):640-5.

- 396 17. Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A, Placek W, Osowski A, Wojtkiewicz J. Articular
397 Cartilage Aging-Potential Regenerative Capacities of Cell Manipulation and Stem Cell Therapy. *Int J Mol*
398 *Sci.* 2018;19(2).
- 399 18. Lavasani M, Lu A, Thompson SD, Robbins PD, Huard J, Niedernhofer LJ. Isolation of muscle-
400 derived stem/progenitor cells based on adhesion characteristics to collagen-coated surfaces. *Methods Mol*
401 *Biol.* 2013;976:53-65.
- 402 19. Lavasani M, Lu A, Peng H, Cummins J, Huard J. Nerve growth factor improves the muscle
403 regeneration capacity of muscle stem cells in dystrophic muscle. *Hum Gene Ther.* 2006;17(2):180-92.
- 404 20. Deasy BM, Gharaibeh BM, Pollett JB, Jones MM, Lucas MA, Kanda Y, et al. Long-term self-renewal
405 of postnatal muscle-derived stem cells. *Mol Biol Cell.* 2005;16(7):3323-33.
- 406 21. Vella JB, Thompson SD, Bucsek MJ, Song M, Huard J. Murine and human myogenic cells identified
407 by elevated aldehyde dehydrogenase activity: implications for muscle regeneration and repair. *PLoS One.*
408 2011;6(12):e29226.
- 409 22. Lavasani M, Robinson AR, Lu A, Song M, Feduska JM, Ahani B, et al. Muscle-derived
410 stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model. *Nat Commun.*
411 2012;3:608.
- 412 23. Adachi N, Sato K, Usas A, Fu FH, Ochi M, Han CW, et al. Muscle derived, cell based ex vivo gene
413 therapy for treatment of full thickness articular cartilage defects. *J Rheumatol.* 2002;29(9):1920-30.
- 414 24. Kuroda R, Usas A, Kubo S, Corsi K, Peng H, Rose T, et al. Cartilage repair using bone
415 morphogenetic protein 4 and muscle-derived stem cells. *Arthritis Rheum.* 2006;54(2):433-42.
- 416 25. Song M, Lavasani M, Thompson SD, Lu A, Ahani B, Huard J. Muscle-derived stem/progenitor cell
417 dysfunction in *Zmpste24*-deficient progeroid mice limits muscle regeneration. *Stem Cell Res Ther.*
418 2013;4(2):33.
- 419 26. Leung GK, Schmidt WK, Bergo MO, Gavino B, Wong DH, Tam A, et al. Biochemical studies of
420 *Zmpste24*-deficient mice. *J Biol Chem.* 2001;276(31):29051-8.
- 421 27. Greising SM, Call JA, Lund TC, Blazar BR, Tolar J, Lowe DA. Skeletal muscle contractile function
422 and neuromuscular performance in *Zmpste24* (-/-) mice, a murine model of human progeria. *Age (Dordr).*
423 2011.

- 424 28. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, et al. Zmpste24 deficiency in mice
425 causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl
426 Acad Sci U S A. 2002;99(20):13049-54.
- 427 29. Pendas AM, Zhou Z, Cadinanos J, Freije JM, Wang J, Hultenby K, et al. Defective prelamin A
428 processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat
429 Genet. 2002;31(1):94-9.
- 430 30. Badame AJ. Progeria. Arch Dermatol. 1989;125(4):540-4.
- 431 31. Chuchana P, Mausset-Bonnefont AL, Mathieu M, Espinoza F, Teigell M, Toupet K, et al. Secreted
432 alpha-Klotho maintains cartilage tissue homeostasis by repressing NOS2 and ZIP8-MMP13 catabolic axis.
433 Aging (Albany NY). 2018;10(6):1442-53.
- 434 32. Wu W, Billingham RC, Pidoux I, Antoniou J, Zukor D, Tanzer M, et al. Sites of collagenase
435 cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their
436 relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis
437 Rheum. 2002;46(8):2087-94.
- 438 33. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5
439 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005;434(7033):644-8.
- 440 34. Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan MF, Ferguson CM, et al. Microarray
441 analysis reveals age-related differences in gene expression during the development of osteoarthritis in
442 mice. Arthritis Rheum. 2012;64(3):705-17.
- 443 35. Choocheep K, Hatano S, Takagi H, Watanabe H, Kimata K, Kongtawelert P, et al. Versican
444 facilitates chondrocyte differentiation and regulates joint morphogenesis. J Biol Chem.
445 2010;285(27):21114-25.
- 446 36. Peffers M, Liu X, Clegg P. Transcriptomic signatures in cartilage ageing. Arthritis Res Ther.
447 2013;15(4):R98.
- 448 37. Stoop R, van der Kraan PM, Buma P, Hollander AP, Billingham RC, Poole AR, et al. Type II
449 collagen degradation in spontaneous osteoarthritis in C57Bl/6 and BALB/c mice. Arthritis Rheum.
450 1999;42(11):2381-9.

- 451 38. Roughley PJ, Melching LI, Recklies AD. Changes in the expression of decorin and biglycan in
452 human articular cartilage with age and regulation by TGF-beta. *Matrix Biol.* 1994;14(1):51-9.
- 453 39. Martin JA, Buckwalter JA. The role of chondrocyte senescence in the pathogenesis of osteoarthritis
454 and in limiting cartilage repair. *J Bone Joint Surg Am.* 2003;85-A Suppl 2:106-10.
- 455 40. Munoz-Lorente MA, Cano-Martin AC, Blasco MA. Mice with hyper-long telomeres show less
456 metabolic aging and longer lifespans. *Nat Commun.* 2019;10(1):4723.
- 457 41. Nguyen KC, Cho KA. Versatile Functions of Caveolin-1 in Aging-related Diseases. *Chonnam Med*
458 *J.* 2017;53(1):28-36.
- 459 42. Min TU, Sheng LY, Chao C, Jian T, Guang GS, Hua LG. Correlation between osteopontin and
460 caveolin-1 in the pathogenesis and progression of osteoarthritis. *Exp Ther Med.* 2015;9(6):2059-64.
- 461 43. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. *Nat*
462 *Rev Mol Cell Biol.* 2007;8(9):729-40.
- 463 44. Gharaibeh B, Lavasani M, Cummins JH, Huard J. Terminal differentiation is not a major
464 determinant for the success of stem cell therapy - cross-talk between muscle-derived stem cells and host
465 cells. *Stem Cell Res Ther.* 2011;2(4):31.
- 466 45. Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, et al. Telomerase reactivation
467 reverses tissue degeneration in aged telomerase-deficient mice. *Nature.* 2011;469(7328):102-6.
- 468 46. Gosselin K, Abbadie C. Involvement of Rel/NF-kappa B transcription factors in senescence. *Exp*
469 *Gerontol.* 2003;38(11-12):1271-83.
- 470 47. Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E, Chang HY. Motif module map reveals
471 enforcement of aging by continual NF-kappaB activity. *Genes Dev.* 2007;21(24):3244-57.
- 472 48. Tilstra JS, Clauson CL, Niedernhofer LJ, Robbins PD. NF-kappaB in Aging and Disease. *Aging*
473 *Dis.* 2011;2(6):449-65.
- 474 49. Kriete A, Mayo KL, Yalamanchili N, Beggs W, Bender P, Kari C, et al. Cell autonomous expression
475 of inflammatory genes in biologically aged fibroblasts associated with elevated NF-kappaB activity. *Immun*
476 *Ageing.* 2008;5:5.
- 477 50. Adler AS, Kawahara TL, Segal E, Chang HY. Reversal of aging by NFkappaB blockade. *Cell Cycle.*
478 2008;7(5):556-9.

- 479 51. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. *Cell*. 2011;146(5):682-95.
- 480 52. Lotz MK, Carames B. Autophagy and cartilage homeostasis mechanisms in joint health, aging and
481 OA. *Nat Rev Rheumatol*. 2011;7(10):579-87.
- 482 53. Matsuzaki T, Alvarez-Garcia O, Mokuda S, Nagira K, Olmer M, Gamini R, et al. FoxO transcription
483 factors modulate autophagy and proteoglycan 4 in cartilage homeostasis and osteoarthritis. *Sci Transl Med*.
484 2018;10(428).
- 485 54. Akasaki Y, Hasegawa A, Saito M, Asahara H, Iwamoto Y, Lotz MK. Dysregulated FOXO
486 transcription factors in articular cartilage in aging and osteoarthritis. *Osteoarthritis Cartilage*.
487 2014;22(1):162-70.
- 488 55. Kwok J, Onuma H, Olmer M, Lotz MK, Grogan SP, D'Lima DD. Histopathological analyses of
489 murine menisci: implications for joint aging and osteoarthritis. *Osteoarthritis Cartilage*. 2016;24(4):709-18.

490

491 **FIGURE LEGENDS**

492

493 **Fig. 1** Alteration in Gene Expression Profile of Articular Cartilage in *Zmpste24*-deficient (*Zmpste24*^{-/-})
494 Progeroid Mice. Articular cartilage from 5-6 month-old young wild type (*n* = 6) and age-matched *Zmpste24*^{-/-}
495 littermate knee joints (*n* = 5) were analyzed for the mRNA expression level of **(a-c)** genes encoding pro-
496 inflammatory cytokines and senescence-associated secretory phenotype (SASP) factors (*Il1a*, *Il6*, and *Tnf*),
497 extracellular matrix (ECM) proteinases (*Mmp3*, *Mmp13*, and *Adamts5*), ECM components (*Col1a1*,
498 *Col2a1*, *Acan*, *Vcan*, and *Bgn*) using qRT-PCR. **(d-e)**. Genes associated with telomere protection (*Port1b*),
499 autophagy suppression (*Mtor*), antioxidant response (*Gpx4*), and oxidative stress-response (*Sod1*).
500 Expression values are relative to *Gapdh* and *Hmbg1*. Data are mean ± SEM. ***p* < 0.01, ****p* < 0.001, #*p* <
501 0.0001, **p* < 0.000001, ns: not significant using two-tailed, unpaired Student's *t*-test or Welch's unequal
502 variance *t*-test.

503

504 **Fig. 2** Effect of Young MDSPC Systemic Transplantation in the *Zmpste24*^{-/-} Progeroid Mouse Articular
505 Cartilage Microenvironment. **(a)** Schematic illustrating the experimental design. **(b-d)** Quantitation of pro-
506 inflammatory cytokines and SASP markers (*Il1a*, *Il6*, and *Tnf*) and anti-inflammatory cytokine (*Il10*),

507 extracellular matrix (ECM) proteinases (*Mmp3*, *Mmp13*, and *Adamts5*), and ECM components (*Col1a1*,
508 *Col2a1*, *Acan*, *Vcan*, and *Bgn*) relative mRNA levels, measured by qRT-PCR from the knee articular
509 cartilage of *Zmpste24^{-/-}* mice intraperitoneally (IP) injected with MDSPCs (Z-IP, *n* = 7) or PBS (Z-PBS, *n* =
510 9). Expression values are relative to *Gapdh* and *Hmbg1*. Data are mean ± SEM. **p* < 0.05, ***p* < 0.01, ****p*
511 < 0.001, #*p* < 0.0001, §*p* < 0.00001, **p* < 0.000001, ns: not significant using two-tailed, unpaired Student's
512 *t*-test or Welch's unequal variance *t*-test.

513
514 **Fig. 3** Systemic Transplantation of young MDSPCs Promotes a Healthy Cartilage Homeostasis in
515 *Zmpste24^{-/-}* Progeroid Mice. Relative mRNA levels were measured by qRT-PCR from the knee articular
516 cartilage of *Zmpste24^{-/-}* mice intraperitoneally (IP) injected with MDSPCs (Z-IP, *n* = 7) or PBS (Z-PBS, *n* =
517 9) and analyzed for the presence of (a) a key ageing signaling pathway mediator (*Nfkb1*), its inhibitor
518 (*Nfkbia*), autophagy and pro-longevity markers (*Foxo1* and *Foxo3*), and telomere protection (*Port1b*), (b)
519 antioxidant response (*Gpx4*), oxidative stress-response (*Sod1*), and growth arrest and DNA damage
520 response (*Gadd45a*), (c) endocytosis and stress-induced senescence (*Cav1*), the cellular
521 senescence/tumor suppressor mechanism (*cdnk2a*), and the mammalian target of rapamycin (*Mtor*) genes.
522 Expression values are relative to *Gapdh* and *Hmbg1*. Data are mean ± SEM. ***p* < 0.01, ****p* < 0.001, #*p* <
523 0.0001, §*p* < 0.00001, **p* < 0.000001, ns: not significant using two-tailed, unpaired Student's *t*-test or
524 Welch's unequal variance *t*-test (a-c and e-g).

525
526 **Fig. 4** Histopathology of Articular Cartilage Following Systemic Transplantation of Young MDSPCs in
527 *Zmpste24^{-/-}* Mice. (a) Representative images (20x magnification) of Safranin-O (Saf-O) stained femoral
528 condyle and tibial plateau from PBS- (Z-PBS, *n* = 3) and MDSPC-intraperitoneally transplanted (Z-IP; *n* =
529 3) *Zmpste24^{-/-}* mice at 5-6 months of age. Quantitative histomorphometric analysis shows (b) total cartilage
530 area, (c) percent of Saf-O+ cartilage area, (d) chondrocyte number, and (e) chondrocyte density. Data are
531 mean ± SEM. **p* < 0.05 with two-tailed, unpaired Student's *t*-test.

Figures




Figure 1

Alteration in Gene Expression Profile of Articular Cartilage in *Zmpste24*-deficient (*Zmpste24*^{-/-}) Progeroid Mice. Articular cartilage from 5-6 month-old young wild type (n = 6) and age-matched *Zmpste24*^{-/-} littermate knee joints (n = 5) were analyzed for the mRNA expression level of (a-c genes

encoding pro-inflammatory cytokines and senescence-associated secretory phenotype (SASP) factors (Il1a, Il6, and Tnf), extracellular matrix (ECM) proteinases (Mmp3, Mmp13, and Adamts5), ECM components (Col1a1, Col2a1, Acan, Vcan, and Bgn) using qRT-PCR. (d-e). Genes associated with telomere protection (Port1b), autophagy suppression (Mtor), antioxidant response (Gpx4), and oxidative stress-response (Sod1). Expression values are relative to Gapdh and Hmbg1. Data are mean \pm SEM. **p < 0.01, ***p < 0.001, #p < 0.0001, ¶p < 0.000001, ns: not significant using two-tailed, unpaired Student's t-test or Welch's unequal variance t-test.




Figure 2

Effect of Young MDSPC Systemic Transplantation in the *Zmpste24*^{-/-} Progeroid Mouse Articular Cartilage Microenvironment. (a) Schematic illustrating the experimental design. (b-d) Quantitation of pro-inflammatory cytokines and SASP markers (Il1a, Il6, and Tnf) and anti-inflammatory cytokine (Il10), extracellular matrix (ECM) proteinases (Mmmp3, Mmp13, and Adamts5), and ECM components (Col1a1, Col2a1, Acan, Vcan, and Bgn) relative mRNA levels, measured by qRT-PCR from the knee articular cartilage of *Zmpste24*^{-/-} mice intraperitoneally (IP) injected with MDSPCs (Z-IP, n = 7) or PBS (Z-PBS, n = 9). Expression values are relative to Gapdh and Hmbg1. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.0001, §p < 0.00001, ¶p < 0.000001, ns: not significant using two-tailed, unpaired Student's t-test or Welch's unequal variance t-test.




Figure 3

Systemic Transplantation of young MDSPCs Promotes a Healthy Cartilage Homeostasis in *Zmpste24*^{-/-} Progeroid Mice. Relative mRNA levels were measured by qRT-PCR from the knee articular cartilage of *Zmpste24*^{-/-} mice intraperitoneally (IP) injected with MDSPCs (Z-IP, n = 7) or PBS (Z-PBS, n = 9) and analyzed for the presence of (a) a key ageing signaling pathway mediator (*Nfkb1*), its inhibitor (*Nfkbia*), autophagy and pro-longevity markers (*Foxo1* and *Foxo3*), and telomere protection (*Port1b*), (b) antioxidant response (*Gpx4*), oxidative stress-response (*Sod1*), and growth arrest and DNA damage

response (Gadd45a), (c) endocytosis and stress-induced senescence (Cav1), the cellular senescence/tumor suppressor mechanism (cdnk2a), and the mammalian target of rapamycin (Mtor) genes. Expression values are relative to Gapdh and Hmbg1. Data are mean \pm SEM. ** $p < 0.01$, *** $p < 0.001$, # $p < 0.0001$, § $p < 0.00001$, ¶ $p < 0.000001$, ns: not significant using two-tailed, unpaired Student's t-test or Welch's unequal variance t-test (a-c and e-g).




Figure 4

Histopathology of Articular Cartilage Following Systemic Transplantation of Young MDSPCs in *Zmpste24*^{-/-} Mice. (a) Representative images (20x magnification) of Safranin-O (Saf-O) stained femoral condyle and tibial plateau from PBS- (Z-PBS, n = 3) and MDSPC-intraperitoneally transplanted (Z-IP; n = 3) *Zmpste24*^{-/-} mice at 5-6 months of age. Quantitative histomorphometric analysis shows (b) total cartilage area, (c) percent of Saf-O+ cartilage area, (d) chondrocyte number, and (e) chondrocyte density. Data are mean \pm SEM. * $p < 0.05$ with two-tailed, unpaired Student's t-test.